Why we do what we do? Making sense of antithrombotic therapy in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention

JACC Cardiovasc Interv. 2010 Jun;3(6):678-9. doi: 10.1016/j.jcin.2010.04.003.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Angioplasty, Balloon, Coronary* / adverse effects
  • Angioplasty, Balloon, Coronary* / mortality
  • Drug Therapy, Combination
  • Fibrinolytic Agents / adverse effects
  • Fibrinolytic Agents / therapeutic use*
  • Hemorrhage / chemically induced
  • Heparin / therapeutic use
  • Hirudins
  • Hospital Mortality
  • Humans
  • Myocardial Infarction / blood
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / mortality
  • Peptide Fragments / therapeutic use
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
  • Recombinant Proteins / therapeutic use
  • Risk Assessment
  • Risk Factors
  • Thrombosis / blood
  • Thrombosis / etiology
  • Thrombosis / mortality
  • Thrombosis / prevention & control*
  • Time Factors
  • Treatment Outcome

Substances

  • Fibrinolytic Agents
  • Hirudins
  • Peptide Fragments
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Recombinant Proteins
  • Heparin
  • bivalirudin